Lantheus Holdings, Inc. (BIT:1LNTH)
Italy · Delayed Price · Currency is EUR | Market Cap | 5.14B -18.0% |
| Revenue (ttm) | 1.34B +0.6% |
| Net Income | 242.00M +9.7% |
| EPS | 3.61 +17.8% |
| Shares Out | n/a |
| PE Ratio | 21.23 |
| Forward PE | 16.49 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 104 |
| Average Volume | 20 |
| Open | 79.10 |
| Previous Close | 75.80 |
| Day's Range | 79.10 - 79.10 |
| 52-Week Range | 42.02 - 94.94 |
| Beta | n/a |
| RSI | 79.29 |
| Earnings Date | May 7, 2026 |
About Lantheus Holdings
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked o... [Read more]
Financial Performance
In 2025, Lantheus Holdings's revenue was $1.54 billion, an increase of 0.50% compared to the previous year's $1.53 billion. Earnings were $233.56 million, a decrease of -25.25%.
Financial numbers in USD Financial StatementsNews
Lantheus price target raised to $100 from $95 at Mizuho
Mizuho analyst Anthony Petrone raised the firm’s price target on Lantheus (LNTH) to $100 from $95 and keeps an Outperform rating on the shares.
Lantheus price target raised to $115 from $85 at Citizens
Citizens analyst David Turkaly raised the firm’s price target on Lantheus (LNTH) to $115 from $85 and keeps an Outperform rating on the shares. The company delivered another strong quarter
Lantheus price target raised to $94 from $82 at Goldman Sachs
Goldman Sachs analyst Paul Choi raised the firm’s price target on Lantheus (LNTH) to $94 from $82 and keeps a Neutral rating on the shares after its Q1 earnings beat.
Lantheus Holdings Earnings Call Transcript: Q1 2026
Q1 2026 delivered strong results with revenue of $377.3M and solid growth in Neuraceq® and DEFINITY®, while PYLARIFY maintained market leadership. Guidance for 2026 is reaffirmed, with growth acceleration expected in 2027 as new products launch.
Lantheus Reports First Quarter 2026 Financial Results and Provides Business Update
BEDFORD, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (Lantheus or the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to F...
Lantheus price target raised to $97 from $84 at B. Riley
B. Riley analyst Yuan Zhi raised the firm’s price target on Lantheus (LNTH) to $97 from $84 and keeps a Buy rating on the shares. The Q1 reports across the
Lantheus price target raised to $98 from $89 at Truist
Truist analyst Richard Newitter raised the firm’s price target on Lantheus (LNTH) to $98 from $89 and keeps a Buy rating on the shares as part of a broader research
Lantheus price target raised to $95 from $85 at Mizuho
Mizuho analyst Anthony Petrone raised the firm’s price target on Lantheus (LNTH) to $95 from $85 and keeps an Outperform rating on the shares. The firm adjusted estimates and price
Lantheus announces three-month extension of LNTH-2501 PDUFA date
Lantheus (LNTH) announced that the FDA has extended its review of the new drug application for LNTH-2501 by three months to June 29. The extension and revised target Prescription Drug
Lantheus Announces Three-Month Extension of PDUFA Date for LNTH-2501 (Ga 68 edotreotide), a PET Diagnostic Imaging Kit Targeting Somatostatin Receptor-Positive (SSTR+) Neuroendocrine Tumors (NETs)
BEDFORD, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to...
Lantheus price target raised to $110 from $105 at Jefferies
Jefferies analyst Matthew Taylor raised the firm’s price target on Lantheus (LNTH) to $110 from $105 and keeps a Buy rating on the shares. Following comments at a recent conference
Lantheus Holdings Transcript: Leerink Global Healthcare Conference 2026
The company is executing a strategic transition to new products like PYLARIFY TruVu and Neuraceq, with a focus on operational efficiency, portfolio expansion, and market access. Revenue is expected to stabilize in 2026, with significant growth potential in Alzheimer's diagnostics and NET imaging as new approvals and reimbursement changes take effect.
Lantheus announces FDA approval of Pylarify TruVu injection
Lantheus (LNTH) announced that the FDA has approved Pylarify TruVu injection, a new formulation of its F 18 prostate-specific membrane antigen imaging agent. Pylarify TruVu is indicated for positron e...
Lantheus Announces FDA Approval of PYLARIFY TruVu™ (piflufolastat F 18) Injection
New formulation of its widely-used U.S. market-leading PSMA PET imaging agent combines the diagnostic performance of PYLARIFY® (piflufolastat F 18) with the potential for larger batches and greater pa...
Lantheus Holdings Transcript: TD Cowen 46th Annual Health Care Conference
Management outlined a strategic pivot to diagnostics, highlighted operational milestones for new product launches, and provided detailed financial guidance. The Alzheimer's franchise is positioned for growth with next-generation agents, while capital allocation remains disciplined amid ongoing litigation and market evolution.
Lantheus Holdings Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Lantheus Holdings, Inc. - LNTH
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has comm...
Lantheus receives U.S. FDA tentative approval for Lutetium Lu 177
Lantheus (LNTH) Holdings announced that it has received U.S. Food and Drug Administration, FDA, tentative approval for the Abbreviated New Drug Application, ANDA, for Lutetium Lu 177 Dotatate, a radio...
Lantheus price target raised to $89 from $82 at Truist
Truist raised the firm’s price target on Lantheus (LNTH) to $89 from $82 and keeps a Buy rating on the shares. The company posted a PYLARIFY-driven Q4 EPS beat and
Lantheus price target raised to $89 from $82 at Truist
Truist raised the firm’s price target on Lantheus (LNTH) to $89 from $82 and keeps a Buy rating on the shares. The company posted a PYLARIFY-driven Q4 EPS beat and
Lantheus price target raised to $85 from $72 at Mizuho
Mizuho analyst Anthony Petrone raised the firm’s price target on Lantheus (LNTH) to $85 from $72 and keeps an Outperform rating on the shares post the Q4 report. The company
Lantheus price target raised to $85 from $78 at Citizens
Citizens raised the firm’s price target on Lantheus (LNTH) to $85 from $78 and keeps an Outperform rating on the shares. Sales and EPS handily exceeded consensus estimates in Q4,
Lantheus downgraded to Hold from Buy at JonesResearch
JonesResearch downgraded Lantheus (LNTH) to Hold from Buy without a price target following the Q4 report. The company is focusing on its radiodiagnostic portfolio while seeking strategic alternatives ...
Lantheus price target raised to $85 from $75 at TD Cowen
TD Cowen analyst Tara Bancroft raised the firm’s price target on Lantheus (LNTH) to $85 from $75 and keeps a Buy rating on the shares.
Lantheus upgraded to Outperform from Market Perform at William Blair
William Blair upgraded Lantheus (LNTH) to Outperform from Market Perform.
William Blair upgrades Lantheus to Outperform on expected return to growth
William Blair analyst Andy Hsieh upgraded Lantheus (LNTH) to Outperform from Market Perform after the company reported Q4 results and provided an update on recent progress. While the firm acknowledges